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This report summarizes the 7th meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF), Washington
DC, November 18–19, 2012. The theme, “A Future Free of Lymphatic Filariasis: Reaching the Vision by Scaling Up,
Scaling Down and Reaching Out”, emphasized new strategies and partnerships necessary to reach the 2020 goal of
elimination of lymphatic filariasis (LF) as a public-health problem.
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The 7th Meeting of the Global Alliance to Eliminate
Lymphatic Filariasis (GAELF) was held 18–19 November,
2012 in Washington, DC. The theme of the meeting, “A
Future Free of Lymphatic Filariasis: Reaching the Vision
by Scaling Up, Scaling Down and Reaching Out”, empha-
sized new strategies and partnerships necessary to reach
the 2020 goal of elimination of lymphatic filariasis (LF) as
a public-health problem. The meeting was held at the
World Bank, back to back with a Uniting to Combat
Neglected Tropical Diseases (NTDs) forum, in order to
capitalize on common themes, participants, and support
(http://www.unitingtocombatntds.org).Current status
The World Health Organization’s overall goal is univer-
sal health coverage with essential public health interven-
tions, including access to preventive chemotherapy (PC)
for NTDs. The goal of integrated PC is to eliminate LF,
onchocerciasis, blinding trachoma and, in some cases,
schistosomiasis as public-health problems and eliminate
childhood morbidity related to soil-transmitted helmin-
thiases (STH). Given that 1.4 billion people require mass
drug administration (MDA), a type of PC, for LF, the LF
programme’s community-based MDA is often used as the
platform for integrating PC diseases. Successful scale upCorrespondence: mbrady@rti.org
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stated.for LF MDA can also cover the majority of the 1.9 billion
people needing PC for at least one NTD.
The current status of the Global Programme to Elimin-
ate Lymphatic Filariasis (GPELF) is that 73 countries are
endemic, with 1.39 million people at risk, 120 million
people infected, and 40 million people affected by LF-
related morbidity. The goal of global elimination has two
parts: i) to stop the spread of infection and interrupt trans-
mission through MDA and ii) to reduce human suffering
through managing morbidity and preventing disability
(MMDP). The first part of the goal is realized through the
sequential activities of mapping, MDA, post-MDA surveil-
lance and verification. In 2011, 53 countries implemented
MDA, with nearly 539 million people treated, and 12
countries under post-MDA surveillance. The second part
is achieved through analyzing the MMDP situation in
country, developing a plan, and providing access to a
minimum package of MMDP care. In contrast to the suc-
cess at scaling up MDA, only 27 countries have reported
MMDP activities.
Progress towards milestones in the GPELF Strategic
Plan 2010–2020 has been impressive. Revised M&E guid-
ance, including information on implementing Transmis-
sion Assessment Surveys (TASs) and verifying absence of
transmission, has been published. A provisional strategy
for interrupting transmission in loiasis co-endemic areas,
where MDA with ivermectin cannot be implemented due
to concerns of serious adverse reactions, will be presented
to the Strategic and Technical Advisory Group on NTDsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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grammatic guidance, including metrics for reporting on
MMDP activities to WHO, will be finalized in 2013.
Country case studies
A series of country case studies highlighted common
themes necessary to achieve success and overcome chal-
lenges. Success in scaling up was bolstered by cultivating
dedicated programme managers, maintaining government
commitment at all levels, and building on existing delivery
platforms. Presentations on success in scaling down show-
cased the importance of government support lasting
beyond MDA, as well as providing ongoing technical as-
sistance for post-MDA surveillance and dossier develop-
ment. Countries facing significant challenges were often
those in post-conflict situations, with poor infrastructure
and weak health care systems. Overcoming these chal-
lenges takes innovative thinking about delivery strategies,
the creation of novel ways to motivate volunteers, and ex-
ternal financial and technical support. Finally, case studies
on accelerating progress showed the importance of im-
proving coverage in areas with ongoing MDA before scal-
ing up, and the critical need to build the capacity of LF
programme managers to plan, budget and monitor pro-
grammes, especially in large, decentralized countries.
Participants learned about pioneering efforts to manage
morbidity and prevent disability, including Togo’s national
lymphoedema programme, a community-based lymphoe-
dema project in a highly-endemic area of India, and the
African LF Morbidity Project. Providing care for LF-related
disease was shown to increase acceptability and compli-
ance with MDA. The group welcomed the results of a clin-
ical trial which showed that doxycycline reversed or halted
progression to later stages of lymphoedema more effect-
ively than amoxicillin or placebo, in patients with and
without active LF infection. The importance of linking
MMDP with other diseases, reporting on MMDP activities
to WHO, and collecting data on surgical complications
and recurrence was discussed.
A session on linking LF programmes with other disease
programmes explored the rationale and opportunities for
coordinating with onchocerciasis, STH, trachoma, and
malaria activities. Opportunities for synergy with onchocer-
ciasis and trachoma activities include integrated mapping,
joint training, combined treatment registers, simultaneous
MDA where feasible, and joint M&E. STH activities greatly
benefit from the LF programme; in 2010, WHO reported
that 57% of the school-aged children treated for STH were
given these medicines through national LF programmes.
However, like MMDP activities in LF programmes, inter-
ventions related to water, sanitation and hygiene often lag
behind PC interventions in STH programmes. Both pro-
grammes need to bolster these supportive activities if the
2020 goal to eliminate LF is to be achieved. LF and malariaactivities also complement each other: LF MDA helps
lower anemia, provides community networks for bednet
monitoring, and influences adults to use bednets to avoid
LF-related disease, while bednets help reduce LF transmis-
sion. An animated discussion followed the presentation of
data from ongoing entomological monitoring in Nigeria
which found no infective mosquitoes after bednet distribu-
tion in areas with LF MDA.
Moving forward
Various speakers highlighted challenges to achieving the
2020 goal, including: i) building the capacity of LF
programme managers and NTD teams to plan, imple-
ment and monitor activities; ii) scaling up to 100% geo-
graphical coverage for MDA while coordinating with
other PC diseases and vector control activities; iii) plan-
ning for TAS, including ensuring the availability and
affordability of diagnostic tests; iv) developing effective
post-MDA surveillance tools and methods; and v) scaling
up MMDP activities to provide access to all patients.
To respond to these challenges, policy, advocacy, imple-
mentation and operational research should be approached
using a network of partners, including Ministries of Health,
WHO, GAELF, GPELF, academia, and non-governmental
development organizations. Developing strategic partner-
ships based on understanding the motivations of each part-
ner was seen as a key to success to collaboration with
other disease programmes, private business, and media or-
ganizations. Presenters also stressed the need to build cap-
acity of dynamic programme managers, increase support
for MMDP, use integration as an opportunity to scale
up, and continue to galvanize government commitment
to LF programmes.
The continuing importance of GAELF as one in a mix
of NTD alliances was evident, with the GAELF 7 meeting
providing an opportunity to celebrate successes, reflect on
ongoing challenges, and share information among circa
250 representatives from country programmes, donors,
and the research community. The future of GAELF as a
forum for discussion and advocacy will be improved by in-
creasing country participation and engagement in the
daily work of the GAELF. The group was challenged to
continue GAELF’s evolution – already a great example of
a ‘mass uprising of compassion’ through its treatment of
millions of at-risk people - by maintaining focus on inter-
rupting LF transmission while expanding its peripheral vi-
sion to include those with LF-related disease.
Opening session – are we on track for 2020?
Welcome by the chair of the GAELF
Dr Patrick Lammie (Centers for Disease Control and Pre-
vention (CDC), USA) welcomed participants to the GAELF
meeting, following on from the successful Uniting to Com-
bat NTD forum (Additional file 1). He thanked Dr Don
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meeting, the Bill & Melinda Gates Foundation (BMGF)
team for arranging the meeting venue logistics, and Glax-
oSmithKline (GSK) and Merck & Co., Inc. for their drug
donations and consistent support of GAELF. He also gave
a special welcome to the newest GAELF partner – Eisai
Inc. – which will donate diethylcarbamazine (DEC) starting
in 2013.
He asked the group to remember two colleagues, Dr
Vely Jean Francois, the programme manager for LF and
malaria in Haiti and Dr Likezo Mubila, the WHO Africa
Region focal point for NTDs, who were at the last GAELF
meeting in South Korea, but have since passed away. Dr.
Jean Francois’ commitment to improving health was a
source of inspiration. During a period of civil strife, he
was kidnapped and held for ransom, but upon his release
chose to stay in Haiti and continue his public health work.
Sadly, he died before seeing the LF programme reach na-
tional coverage in 2012. Dr Likezo Mubila, was ‘our con-
science’, always reminding the group of the countries and
communities left behind. Dr Lammie expressed hope that
when GAELF members debate ways to reach our targets
in all communities, we hear her voice reminding us of that
obligation.
He closed by noting while we can celebrate successes,
we need to be mindful about finding new strategies and
partnerships to reach the ambitious 2020 objective of
elimination of LF.
Welcome by the Minister of Health, Tanzania
Dr Hussein Mwinyi (Honorable Minister of Health,
Tanzania) remarked that it was good to be back among
old friends, having been involved in the early days of
GAELF. Dr Mwinyi was first struck by the suffering of
elephantiasis patients when he was a member of parlia-
ment from a highly-endemic district. That experience
motivated him to start the Tanzanian LF programme as
a way to signal hope for the neglected populations in
endemic communities.
He expressed delight at the progress GAELF has made
in a relatively short time, including the number of
people treated and the number of countries with active
programmes. The clear goal of elimination – with the
countries at the centre – has resulted in tremendous
achievements, although it is essential to upscale faster,
especially in parts of sub-Saharan Africa and Indonesia,
and monitor progress closely.
He noted many of the outstanding needs of the
GAELF, such as improved tools for ongoing post-MDA
surveillance, stronger morbidity programmes, strategies
for MDA in urban areas, and operational research guided
by programme needs. He highlighted how the Tanzanian
President established a fund to support LF patients, but
there is still a major backlog of hydrocele surgeriesneeded. He challenged the group to report on progress of
morbidity burden assessment and activities at the next
GAELF meeting.
Dr Mwinyi emphasized that partnership and coordin-
ation are key components of the effectiveness of GAELF,
encouraging the group to re-examine what the GAELF
can learn and share with other NTD alliances and to use
GAELF’s momentum to meet NTD goals.
Preventive chemotherapy and WHO’s strategic
plan for NTDs
Dr Dirk Engels (WHO Department of Control of NTDs,
Geneva) discussed how WHO is focusing on universal
health coverage with essential public health interven-
tions, including access to preventive chemotherapy (PC)
for NTDs. The medicines used in PC for LF, onchocer-
ciasis, soil-transmitted helminthiases (STH), schistosom-
iasis and trachoma are all safe, single dose medicines
that can be used without prior individual diagnosis. The
rationale for expanding integrated PC is that the same
individuals in poor environments are affected by multiple
diseases and programmes have an ethical responsibility to
treat all diseases. Integrating and coordinating PC inter-
ventions can result in increased cost-effectiveness, feasibil-
ity, visibility, acceptability, and can reduce the risk of drug
resistance. Given that 1.4 billion people require PC for LF
and that LF drug distribution is community based, LF is
often used as the platform for integrating PC diseases.
Other strategic components overlap among the disease
programmes, such as morbidity management (LF, schisto-
somiasis, trachoma), vector control (LF, onchocerciasis,
schistosomiasis) and water and sanitation (schistosomia-
sis, STH, trachoma).
He noted that the goal of integrated PC is to eliminate
LF, onchocerciasis, blinding trachoma and in some cases
schistosomiasis as public health problems and eliminate
childhood morbidity related to soil-transmitted helmin-
thiases by 2020. This will be achieved by scaling up PC
for all diseases to full national scale as quickly as possible,
and enhancing these interventions through integrated
planning, implementation and management. Steps for roll-
ing out integrated PC include: i) institutionalizing a NTD
task force, ii) developing a national plan of action through
situational analysis, action planning and mapping, and
identifying funding gaps, and iii) holding a stakeholders
meeting to mobilize resources and coordinate partners.
Currently, 1.9 billion people in 124 countries require
PC for at least one of the diseases, with 710 million
treated in 2010. The WHO South-East Asia Region has
53% of the burden and the African Region has 31%. Spe-
cifically for LF, 1.4 billion people in 73 countries require
MDA, with 539 million treated in 2010–2011. The South-
East Asia Region has 63% of the global burden of LF, while
the Africa Region has 31%. Thus successful scale up for
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of PC (Figure 1).
However, Dr Engels cautioned that there is still a need to
sustain the impact of LF MDA through non-LF PC once
the LF programme scales down, particularly for STH and
onchocerciasis. While there often will be a shift to school-
based PC after LF MDA ends in some areas, some pro-
grammes will still need community-based interventions.
LF strategic plan
Dr Kazuyo Ichimori (WHO Department of Control of
NTDs, Geneva) presented the current status of the
Global Programme to Eliminate Lymphatic Filariasis
(GPELF) as 73 countriesa endemic for LF, 1.39 billion
people at risk, 120 million infected, and 40 million
people affected by morbidity. The goal of global elimin-
ation has two parts: i) to stop the spread of infection
and interrupt transmission through MDA and ii) to re-
duce human suffering through managing morbidity and
preventing disability (MMDP). In 2011, 53 countries im-
plemented MDA, with 538.6 million people treated in
2010–2011, and 12 countries under post-MDA surveil-
lance. However, only 27 countries reported MMDP ac-
tivities to WHO. Baseline sentinel site data from 37
countries showed an average microfilaraemia prevalence
of 12.6%, which dropped to 2.7% according to mid-term
sentinel site data from 36 countries.
Dr Ichimori then summarized the GPELF Strategic
Plan 2010–2020 [1], which was developed largely as a
result of conversations at the last GAELF meeting in
Korea [2]. The vision of the strategic plan is a world
without the risk of LF through global elimination of LF as
a public-health problem. The objective for the MDAA
Figure 1 Overlap between population requiring PC for all diseases an
PC 1.9 billion. B: Population requiring MDA for LF 1.39 billion. AFR: Africa R
Europe Region, SEAR: South East Asia Region; WPR: Western Pacific Region.component is to reduce infection prevalence below target
thresholds in all endemic areas, with targeted prevalence
levels defined for various species/vector complexes. This
is achieved through stepwise activities of mapping, MDA,
post-MDA surveillance, and verification (Figure 2).
In order to achieve the MDA goal, the strategic plan
included four milestones for 2011–2013: i) revised moni-
toring and evaluation (M&E) guidance, ii) criteria for
verifying absence of transmission, iii) provisional strategy
for interrupting transmission in loiasis-endemic areas,
and iv) final strategy for interrupting transmission in
loiasis-endemic areas. The M&E manual, which includes
guidance on verifying absence of transmission, has been
published [3]. The provisional strategy for loiasis-endemic
areas has been recommended to the Strategic and Tech-
nical Advisory Group for NTDs for endorsement in April
2013 [4]. The MDA target is that by 2020 70% of countries
will be verified free of LF and the other 30% will be
under post-MDA surveillance. As of 2011, 19 countries
had not started MDA, 41 were implementing MDA, 12
were under post-MDA surveillance, and nine had been
verified free of LF.
The target for the MMDP component is no new clinical
cases, measured by i) reduction in the number of acute
attacks, ii) the number of hydrocele patients cured, and
iii) the MMDP geographical coverage in LF-endemic
countries. This is achieved through analyzing the MMDP
situation in country, developing a plan, and providing a
minimum package of MMDP care (Figure 3).
In order to achieve the MMDP goal, the strategic plan
included two milestones for 2011–2013: i) revised guide-
lines and training modules for MMDP, and ii) metrics
developed for annual reporting on MMDP activities toB
d population requiring MDA for LF. Legend: A: Population requiring
egion, AMR: Americas Region, EMR: Eastern Mediterranean Region; EUR:
Mapping Verification
Post-MDA
surveillance
MDA
Figure 2 Programmatic steps: MDA component.
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the MMDP manual for programme managers, which in-
cludes indicators and forms for reporting to WHO, is
currently in draft. The MMDP target is that by 2020
100% of endemic countries will have achieved full geo-
graphical coverage and access to basic MMDP care.
Critical challenges include: increasing LF MDA cover-
age to 100% while coordinating with other PC diseases
and vector control; planning for TAS; ensuring availabil-
ity and affordability of diagnostic tests; developing effect-
ive post-MDA surveillance tools; defining the role of the
regional programme review groups and the Strategic and
Technical Advisory Group for NTDs in the verification
process; scaling up MMDP activities; and collecting evi-
dence on best practices of linking MMDP activities with
health services. These challenges can be best met by
using a network of partners and integrated approaches
(Figure 4) to work on policy, advocacy, implementation,
and operational research.Regional progress
Dr Ricardo Thompson (National Institute of Health,
Mozambique) presented the status of the Programme to
Eliminate LF in each of the WHO Regions: African Region,
Americas Region, Eastern Mediterranean Region, South-
East Asia Region, and the Western Pacific Region. DespiteMDA
Plan Min
o
Situation
analysis
M
Figure 3 Programmatic steps: MMDP component.success in scaling up MDA, regions face challenges as they
reach the peak of delivering required treatments, while
simultaneously needing to build capacity to implement
TAS to evaluate success. He presented regional statistics
on the number of countries and people requiring MDA,
the number treated, and country status (Table 1 and
Figure 5).African Region
The African Region has achieved remarkable progress in
scaling up effective MDA since 2000, with 76% coverage
of total population in areas with MDA in 2011. However,
by 2015 both the number of countries conducting MDA
and the number treated must be doubled. In particular,
the countries which have not finished mapping or
started MDA, mostly in Central Africa, must start, espe-
cially now that guidelines for MDA in loiasis-endemic
areas are available. The region faces logistical and polit-
ical challenges which have delayed completion of map-
ping and initiation of MDA. Heavy burden countries
such as the Democratic Republic of Congo, Nigeria and
Ethiopia need specific plans to aid in scaling up, includ-
ing consideration of alternatives to annual MDA to ac-
celerate the progress of interruption of transmission.
The regional partnership is being strengthened to sup-
port country implementation.Post-MDA
Surveillanceimum pack ge 
f MMDP care
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Figure 4 Working together to meet the GPELF goal. Legend: A: Integration: MMDP, vector control and MDA. B: Partnership: Collaboration to
support one GPELF. MDA: mass drug administration; SCH: schistosomiasis; STH: soil-transmitted helminthiases; TRA: trachoma; ONCHO: onchocerciasis;
VC: vector control; IVM: integrated vector management; GPELF: Global Programme to Eliminate Lymphatic Filariasis; MMDP: morbidity management
and disability prevention; GAELF: Global Alliance to Eliminate Lymphatic Filariasis; NGDO: non-governmental development organization; MOH: ministry
of health.
Table 1 Number of countries and people requiring MDA
and number treated, by WHO Region
Region No. of
countries
requiring
LF MDA
Total
population
(m) requiring
MDA
No. people
(m) treated
in 2011
Africa 34 443 113
Americas 4 12 9
Eastern Mediterranean 4 22 0.5
South-East Asia 9 879 414
Western Pacific 22 37 21
TOTAL 73 1,393 557.5
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The high burden of LF in Haiti, which constitutes 80% of
the Americas burden, presents a special situation, espe-
cially after the earthquake in 2010 which destroyed much
of the government’s infrastructure. However, LF MDA in
2012 achieved full national coverage for the first time
helped, in part, by the strong regional partnership that in-
cludes Ministries of Health and Education, IMA World
Health, University of Notre Dame, US Centers for Disease
Control and Prevention (CDC), United States Agency for
International Development (USAID), Inter-American De-
velopment Bank, and the Global Network for NTDs. In
addition, a bi-national project to eliminate malaria in Haiti
and the Dominican Republic will also have positive effects
for the LF programme.
Eastern Mediterranean Region
The Eastern Mediterranean Region showed a peak in
treatments in 2004, with numbers of people treated dras-
tically falling off from 2005 onwards, since two of the LF-
endemic countries are moving towards elimination and
scaling down treatments, while the fragile infrastructure
in Sudan and South Sudan has made it difficult to upscale
MDA. Yemen and Egypt now need to procure immuno-
chromatographic tests (ICTs) to carry out TAS since all
implementation units (IUs) have implemented at least
eight rounds of MDA and achieved <1% microfilaraemia
rates in sentinel and spot-check sites. In addition, the re-
gion needs to strengthen morbidity management.
South-East Asia Region
All the LF-endemic countries in the South-East Asia
Region are implementing MDA, except Sri Lanka andMaldives which are under post-MDA surveillance. While
the high-burden countries of Bangladesh and India have
made significant progress in implementing MDA, they are
facing difficulties procuring ICTs for implementing TAS.
Political instability in Timor Leste led to the interruption
of MDA, which has not restarted. The region also must
strengthen the commitment of implementation partners
in the region and scale up MMDP activities.
Western Pacific Region
In the Western Pacific Region, three countries have not
started MDA, nine have ongoing MDA and ten are under
post-MDA surveillance. Challenges include availability and
affordability of ICTs, reaching prevalence goals in areas
with Aedes vectors where repeated MDA rounds have not
lowered levels adequately, and strengthening MMDP activ-
ities. Scaling up MDA in Papua New Guinea (PNG)
continues to be a major task. Finally, there is a lack of
country-level capacity to prepare dossiers for verification,
Figure 5 Status of MDA by country.
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tries progress.
Discussion
In order to truly analyze regional progress, participants
suggested that presenters provide details of the epi-
demiological situations and implementation progress at
an IU level. In addition, the most appropriate way to pro-
vide support to countries – given the multiple demands on
WHO and regional programme review group members -
was debated, with a suggestion to allow decisions by a
country-level review group under the auspices of the re-
gional programme review groups for larger countries.
Given the need to build country and regional capacity to
analyze country situations and review programme pro-
gress, participants were asked to give specific ideas on
short- and medium-term capacity building needs to Profes-
sor David Molyneux, who is chair of the WHO NTD
working group on capacity building. Finally, an update on
the new ICT platform was provided: it is currently
undergoing field evaluation, and the effect of the new
test format on TAS guidance will be reviewed after the
results are compiled. A small group of partners is in dis-
cussion with Alere, the company that produces the ICTs
who have requested accurate demand forecasts from
country programmes in order to ensure supplies are ad-
equate and timely.
Highlighting success
Highlighting success in scaling up
Moderator: Mr Andy Wright (GlaxoSmithKline, UK).
Haiti: triumph over adversity Dr Abdel Direny (IMA
World Health, Haiti) described the LF situation in Haiti,
where 88% of communes have Bancroftian filariasis,
transmitted by Culex mosquitoes. MDA began in 2000in the Leogane commune and scaled up to 24 communes
by 2005, when it was stopped due to lack of funding. Since
2008, with help from GSK, IMA World Health/USAID,
University of Notre Dame, CDC, and Partners in Health,
the programme has gradually scaled up, reaching full
coverage of 140 communes in 2012. Coverage in the
2011–2012 round of MDA averaged 90% of total popula-
tion, with a range between 80-116% (using population
numbers based on 2003 census data without accounting
for migration). Drugs are administered at distribution
posts and schools, with three community drug distributors
per post. Social mobilization is accomplished through
radio spots, announcements from trucks, and community
leader announcements. The community drug distribution
networks are also used to distribute shoes, water filters,
and essential medicines.
Dr Direny recounted the many challenges of the Haiti
programme, including the 2010 earthquake, cholera out-
breaks, and political instability. The programme needs
to scale up morbidity management, latrine construction,
hygiene activities, and determine how to continue with
STH MDA after LF MDA is stopped. He emphasized
that these challenges can only be addressed through col-
laboration; integration of LF and STH programmes; and
participation of community leaders, health promoters and
community drug distributors in population sensitization
to ensure sustained interest in participating in MDA. The
triumph of the programme over unavoidable adverse situ-
ations was feasible due to the commitment of government
and partners, the ability to immediately assess and plan
next steps after the earthquake, the contributions from
volunteers, and the consistent use of monitoring and
evaluation to measure impact.
Malawi: an inspirational personal story Mr Square
Mkwanda (LF Programme in the Ministry of Health,
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Malawi, where 26 of 28 districts are endemic, with 14.1
million people at risk. While the country was mapped in
2003, MDA did not start until 2008, after the Minister
of Health was influenced by hearing about other countries’
progress at the 2008 GAELF meeting in Tanzania. Even
though there was no LF-specific budget, Mr Mkwanda
was tasked with rolling out LF MDA in eight districts,
which he achieved through integration with other health
activities, such as distribution of bednets. In order to show
political will and convince the public the drugs were safe,
drugs were distributed in parliament and the state house.
After achieving 80% coverage, the programme scaled up
in 2009 to total geographical coverage, and was able to
use the results of 2008 and 2009 MDA to secure support
from the Centre for Neglected Tropical Diseases (CNTD)
for 2010 onwards. He noted that challenges to eliminate
remain, including cross-border issues, morbidity manage-
ment, and competing government priorities. Although
morbidity management is ongoing, with 3,201 hydroce-
lectomies and 2,008 lymphoedema patients treated over
the past four years, there are gaps in supervising self-
care groups and building capacity of health workers in
case management.
India: impact of government commitment Dr V
Kumaraswami (Consultant, India) presented the status
of LF in India, which accounts for 40% of the global bur-
den with 600 million people at risk and 509 million tar-
geted for MDA in 20 endemic states. MDA for LF was
piloted in the 1950s, with a 2002 national health policy
calling for elimination by 2015. Single-dose DEC MDA
covered all endemic areas by 2004 and DEC + albenda-
zole MDA covered all areas by 2006; however, issues of
social mobilization and compliance still exist. Sentinel
sites show a positive impact of MDA – with an average
1.2% mf rate in 2004, compared to an average of 0.35%
in 2011.
In 2011, the programme was supported by US$10 mil-
lion for MDA and morbidity activities from the central
government, state budget contributions, and a donation
of 300 million albendazole tablets by GSK. Other part-
ners include medical colleges to implement independent
coverage assessments, the Indian Council of Medical Re-
search to assess MDA coverage and implement oper-
ational research, the National Centre for Disease Control
to train, and non-governmental development organiza-
tions to implement and evaluate morbidity activities.
He noted some of the complexities of the Indian
programme, including drug needs (1 billion DEC tablets
and 500 million albendazole tablets a year), quality-
assured drug procurement, storage and distribution of
drugs, training of 2.5 million peripheral health workers,
and treatment of 250 people per day per worker duringMDA. Current critical issues include scaling up morbid-
ity training, hydrocele surgery, and home-based lym-
phoedema care, as well as strategies and funding for
scaling down, as 170 IUs are ready for TAS, necessitat-
ing procurement of 150,000 ICTs in 2013 when TAS ac-
tivities are conducted.
Liberia: capitalizing on existing platforms Dr Karsor
Kollie (LF Programme, Ministry of Health, Liberia) de-
scribed Liberia’s LF programme, which covers the 13 en-
demic counties and an at-risk population of 3.4 million,
in a country that is post-conflict, with a weak health sys-
tem. The LF programme built on the success of the on-
chocerciasis programme, which uses community drug
distributors (CDDs) for MDA and has a mechanism in
place to monitor the impact of MDA. The programme
targeted 1.6 million people in the 13 endemic counties
in 2012, with an aim of 100% coverage in the next two
years. The largest challenges have been the turnover of
CDDs due to poor motivation and logistical issues, such as
the need for motorbikes to reach isolated areas. Integration
with the malaria programme has been helpful to determine
the impact of vector control on MDA and determine the
existence of urban LF transmission. Lessons learned in-
cluded: integration can enhance coordination and out-
comes, use of existing structures increases ability to scale
up, and collaboration with malaria programmes on inte-
grated vector management might speed up LF elimination.
Support for the programme is provided by CNTD,
Sightsavers, WHO and the African Programme for On-
chocerciasis Control (APOC). In addition, LF is now in-
cluded in the 10-year national health policy and essential
package of health services, so government funding will
hopefully increase. Continued government advocacy will
be important, especially as the President of Liberia is now
co-chairman of the United Nations committee shaping
the post-Millennium Development Goals priorities.
Highlighting success in scaling down
Moderator: Dr Adrian Hopkins (Mectizan Donation
Program, USA).
Togo: a first in Africa Dr Monique Dorkenoo (LF
Programme, Ministry of Health, Togo) discussed how
Togo – the only country in Africa that has been able to
stop MDA – was able to scale down. Togo has 1.3
million people at risk of LF in seven districts. MDA
started in one district in 2000, with full geographic scale
achieved in 2003 and continued for at least six years in
all districts until 2009. Every district had a sentinel site
with regular evaluation of microfilaremia levels. In 2008,
all districts were assessed for stopping MDA using the
2005 WHO guidelines. MDA was stopped in five of
seven districts after the 2008 MDA and in two districts
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lenge is how to monitor for, and avoid, resurgence. A
first round of post-MDA surveillance using TAS was im-
plemented in Kozah district in December 2009 as part of
the BMGF-supported global operational research project
and a second round will be implemented in 2012. The
programme aims to maintain advocacy to ensure funding
for post-MDA ongoing surveillance, currently focused in
border areas. It also is working to increase bednet cover-
age and usage to ensure interruption of transmission.
Ghana: gradually scaling up and down Dr Nana-
Kwadwo Biritwum (NTD Programme, Ministry of Health,
Ghana) described how LF activities in Ghana are adminis-
tered in the context of the NTD programme, as every dis-
trict in Ghana is endemic for at least three NTDs. The
population at risk of LF in Ghana is 12 million, in 74 of
170 districts. From 2001–2006, Ghana scaled up MDA
from five districts to all 74 endemic districts. Coverage
surveys were completed in three to ten districts each year.
As of 2010, four districts have stopped MDA. He noted
that the three greatest challenges were i) urban MDA and
community fatigue in rural areas, ii) tools for post-MDA
and non-endemic district surveillance, and iii) limited hu-
man and financial resources. In order to overcome these
challenges, the programme is working to develop alterna-
tive social mobilization and distribution strategies for
urban MDAs, implementing operational research with
CDC on surveillance, and building technical capacity.
Vietnam: planning for dossier development Dr Do
Trung Dung (LF Programme, Ministry of Health, Vietnam)
described LF in Vietnam, where both Bancroftian and
Brugian filariasis are present. One and a half million people
are at risk in 12 districts, which were combined into six
IUs for MDA implementation. From 2003–2008, all six
IUs underwent five rounds of MDA. In 2009, all districts
were assessed for stopping MDA using the 2005 WHO
guidelines. Post-MDA TAS surveys will be implemented in
2013 and in 2015, grouping districts into four evaluation
units. He noted that a major challenge is to conduct TAS
in schools in rural, minority areas due to difficulties obtain-
ing consent for blood collection. The programme aims to
involve teachers and parents with survey teams when col-
lecting blood in these areas. In addition, the programme
will need external financial and technical support, as it has
limited government funding and limited ability to collect
data and technically write the verification dossier.
Philippines: ensuring government support at all levels
Dr Leda Hernandez (Ministry of Health, Philippines) ex-
plained that 28–30 million people are at risk of LF in
the Philippines in 44 endemic provinces. MDA has been
ongoing since 2001 in selected areas, with a peak of 37IUs conducting MDA in 2007 and 2009. As of 2011, 12
provinces stopped MDA, with TAS scheduled for eight
more in 2012. Three IUs have finished post-MDA sur-
veillance, and six others have ongoing surveillance. She
noted that the key drivers of this success have been govern-
ment budget (e.g. for DEC), partnerships to fill gaps and
address morbidity, presence of committed health workers,
and external technical assistance. The programme is ad-
dressing the challenge of ownership and commitment of
local government units by offering performance-based in-
centives for IUs which achieve elimination goals. It also is
holding regular stakeholder meetings to increase coordin-
ation of, and feedback to, partners, especially those from
other sectors; training health workers on new guidelines;
and conducting rapid assessment surveys, operational re-
search, and post-MDA surveillance in order to strengthen
M&E. Finally, the programme is lobbying for the sustain-
ability of the annual LF budget until the elimination goal is
reached –not just until MDA is stopped.
Discussion
Four main issues were discussed following these presenta-
tions. First, the importance of collecting data on baseline
prevalence was stressed, as it is a factor in determining
how many rounds of MDA are necessary. Second, the
challenges of cross-border collaboration and synchroniz-
ing MDA cycles were brought up, with a suggestion to
intensify surveillance in cross-border areas. Third, the sug-
gestion of twice-yearly treatment was put forward to speed
interruption of transmission, especially in places with
twice-yearly onchocerciasis treatment. Finally, it was sug-
gested that it would be helpful if countries found a way to
acknowledge donors and partners to encourage sustained
donations in a tough financial climate.
Meeting programme challenges
Reaching the unreached
Moderator: Professor Moses Bockarie (Center for
Neglected Tropical Diseases, UK).
Sierra Leone: how did Sierra Leone do it? Mr Mustapha
Sonnie (Helen Keller International, Sierra Leone) de-
scribed the LF situation in Sierra Leone, where LF is co-
endemic with onchocerciasis and transmitted by the
Anopheles vector. Despite prior conflict, a poor health
system, and low technical capacity, the programme is on
track to eliminate LF transmission by 2015. Building on
the well-established community-based onchocerciasis
MDA system, the LF MDA was scaled up to national
coverage in the three years from 2007 to 2010. Training
and advocacy follow a cascade from national supervisors
to district health management teams to primary health
unit staff to community drug distributors, with targeted
messages for each. Social mobilization activities include
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areas, and radio programmes.
Mr Sonnie noted that the programme faces challenges
of competing health priorities such as cholera, high
infant and maternal mortality and malaria; poor road in-
frastructure; and motivation of community volunteers.
Community leaders are asked to find ways to motivate
volunteers, such as exemption from communal work,
helping CDDs with farming activities during the harvest
season, and recognition by the community. The national
NTD programme and partners have over the years pro-
vided motivation to volunteers such as free t-shirts and
certificates. In addition, traditional beliefs that equate
elephantiasis with witchcraft mean that the programme
has to reach out to traditional healers to ensure their
buy-in to the MDA. Partners include USAID, DFID,
Helen Keller International, Sightsavers, and CNTD.
Liberia: why is Liberia so optimistic? Ms Marnijina G.
Moore (Marjin) (LF Programme, Ministry of Health,
Liberia) described Liberia’s plan to scale up to 100% geo-
graphic coverage of LF MDA in the next two years. The
programme’s strategy relies on an integrated programme
with onchocerciasis, STH, schistosomiasis, Guinea worm
and Buruli ulcer, led by a single director and a motivated
young team. MDA for LF and STH are being added to
the onchocerciasis community-directed treatment inter-
vention platform, which covers the entire country. Suc-
cess is helped by the relatively small size of the country
of 3.4 million people, and a decentralized health system
that enables counties to plan and implement their own
NTD interventions. Commitment from the government
of Liberia and donors such as APOC, DFID, CNTD and
Sightsavers allowed the programme to add more trained
health workers and CDDs after LF was added to the on-
chocerciasis platform. She remarked that even though
people might not understand the details of the NTD strat-
egy, there is a demand for ivermectin from communities
which made it easy to add albendazole to the MDA. Chal-
lenges of infrastructure, motivation of volunteers, vertical
programmes, a limited government budget, poor inter-
sectoral collaboration, and lack of a mechanism for mor-
bidity management were noted.
Papua New Guinea: why is PNG struggling? Dr Leo
Makita (Malaria and Vector Borne Diseases, Ministry of
Health, PNG) discussed the LF situation in PNG, where
LF is endemic in most districts and transmitted by the
Anopheles vector. Seventy-five percent of the population
lives in rural areas. He noted that PNG’s challenge to
find enough resources to deliver health services to all
areas remains unmet. While the LF programme achieved
success at scaling up MDA in 2004 by integrating with
malaria programme bednet distribution, in the followingyears there were not enough resources to implement LF
MDA alone.
Using the health system to reach those at risk has pro-
duced limited results, due to areas that have no access
to any health services (where health posts might be closed
due to tribal fights), a decentralized system where civil
servants in each district have to be convinced to imple-
ment MDA, the high cost of MDA, the length needed to
complete an MDA using health staff, and unsatisfactory
reporting. In addition, finding health staff to supervise vol-
unteer distributors, drug logistics, and developing social
mobilization strategies for many unique communities has
proven difficult. Other health programmes, such as mal-
aria, have found success using private partners to imple-
ment health activities, such as Rotary’s attainment of 95%
national coverage of bednets in a short time frame.
Dr Makita summarized PNG’s plan to move forward
by grouping villages into manageable populations for
MDA, appointing and training more volunteers, having
MDA on an appointed day in a district, recruiting extra
national staff, and ensuring availability of drugs and ad-
equate information. The new PNG Minister of Health has
renewed the government commitment after attending a
NTD meeting in Australia, and partners such as WHO,
James Cook University, the Institute of Medical Research,
and the private sector are becoming more involved.
Discussion
Participants offered suggestions for the PNG programme,
including a cost comparison of using community volun-
teers versus hiring a third party to implement, piggybacking
on the Expanded Programme on Immunization activities,
looking at cross-border solutions with Indonesia, and ex-
ploring private sector infrastructure networks such as those
distributing cell phones, liquor, etc.
How can we accelerate the process?
Moderator: Dr Frank Richards (The Carter Center, USA).
Indonesia: moving from partial to full coverage
Dr Rita Kusriastuti (Vector Borne Disease Control, Min-
istry of Health, Indonesia) summarized the LF situation,
where 368 of 497 districts are endemic, with 125 million
people at risk of Bancroftian and/or Brugian filariasis.
The programme defines the district as the IU, but many
districts are only able to support MDA in some sub-
districts each year. In 2011, 98 districts conducted MDA,
with 61 covering the entire district and 37 covering only
some sub-districts. In addition, some districts have con-
ducted more than five MDA rounds, but are still endemic.
These issues have led to problems in fully implementing
the elimination strategy, which called for MDA implemen-
tation in 80 districts per year from 2012–2018. To acceler-
ate progress the programme needs to improve programme
Brady Parasites & Vectors 2014, 7:46 Page 11 of 19
http://www.parasitesandvectors.com/content/7/1/46management by strengthening case finding, reporting and
recording; involve the community in the population regis-
tration; increase monitoring of ingestion of the drugs; and
improve the referral system for serious adverse reactions.
In addition, human resource capabilities need to be im-
proved through training in planning and surveillance,
managerial skills, communication skills, and monitoring
and evaluation.
Dr Kusriastuti noted that expansion of the national LF
committee to cover NTDs, advocacy to both high-level
leaders and local government leaders to support oper-
ational costs, integration with the school health programme
for STH, partnerships with other sectors, involvement of
local non-governmental development organizations, and
assistance from international partners such as WHO,
USAID, AusAID, RTI International, Rotary, World Vision,
and the Global Network for NTDs is all critical to achieve
the elimination goal. Although $12 million is already com-
mitted by donors and the government, the Indonesia
programme has a funding gap of $10 million in 2013.
Nigeria: improving integration to assure funding
Mr Chukwu Okoronkwo (NTD Programme, Ministry of
Health, Nigeria) explained that over 106 million people
are at risk of LF in 541 local government units (LGAs)
of the 705 that have been mapped. Only 175 LGAs
(32%) implemented MDA in 2011, covering an at-risk
population of 33 million, but with less than half of the
LGAs achieving the coverage goal of 80% of eligible
population treated. The programme started scaling up
MDA in 2009 in areas co-endemic with onchocerciasis,
with 4.7 million treated in 2009, 10 million treated in
2010 and 22 million treated in 2011. He noted that the
programme intends to complete mapping by March
2013 with USAID and DFID support, conduct baseline
surveys in sentinel sites, provide adequate management
and technical training to improve planning and coordin-
ation skills of State Coordinators, and conduct compre-
hensive census updates. However, plans to accelerate
progress have been hampered by ineffective coverage of
MDA in urban areas, which has brought overall cover-
age rates down. Financial issues of inadequate funding,
late release of approved funds by partners, and depend-
ency on assisting non-governmental development orga-
nizations can be solved by advocacy and sensitization at
the highest levels, improving the integrated NTD platform
implementation to share resources, and mobilizing add-
itional partners. The programme also needs to address the
issue of incentives for CDDs and health workers, as
funds are insufficient. Policymakers’ desire to extend
MDA to areas that are not yet mapped or are non-
endemic have been problematic, so the programme aims
to target more sensitization and advocacy activities to
policymakers at all levels.Tanzania: phasing in integrated MDA
Dr Upendo Mwingira (National NTD Programme, Min-
istry of Health, Tanzania) discussed the integrated NTD
programme on mainland Tanzania, which includes five
PC NTDs and ten case-management NTDs, targeting 44
million people. The programme follows a NTD master
strategic plan, implemented by NTD coordination units
at national, regional and district levels. It uses the LF
MDA as the platform, training health workers, school
teachers and CDDs, and is scaling up MDA through a
phased approach of adding one region each year. In
2011, 11.3 million people were treated for NTDs in 76
implementation units (50% geographic coverage), with
the goal to reach full geographic coverage by 2014. She
noted that the programme needs a NTD database sys-
tem that can send data collected at health center level
directly to national level and can be integrated into the
health management information system in order to over-
come challenges of delays in data collection and reporting.
The programme will encourage increased programme
monitoring, using partner support to maintain at least one
sentinel sites in every region and will increase advocacy
and support for morbidity management at all levels. Other
technical issues include the need for clear tools for all
NTDs, more training, and support for a drug logistician. In
terms of administrative issues, Dr Mwingira remarked that
an integrated country strategic plan and joint planning
meetings are necessary when dealing with multiple part-
ners and donors, including CNTD, the Schistosomiasis
Control Initiative, RTI International, IMA World Health,
Sightsavers, and Helen Keller International. Local advocacy
is necessary to ensure local government contribution and
engage partners from other sectors. The programme sees
opportunities in a strong health system, existing part-
nerships, links to interventions such as Water, sanita-
tion and hygiene (WASH), indoor residual spraying for
malaria, and the global momentum resulting from the
London Declaration.Discussion
Participants remarked on the tension between scaling up
and ensuring appropriate treatment coverage in current
MDA areas, advising that it is important to meet treat-
ment coverage in current areas first before expanding
geographic coverage. Suggestions on improving advocacy
and funding included the use of ministers of parliament
and involving African and Asian Development Banks.
Decentralized systems that have power at district level
can help accelerate progress as services are delivered
nearer the community, freeing the central level to focus
on advocacy and coordination. The issue of finding hot
spots, e.g., clusters of residual transmission, in large dis-
tricts was also raised.
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morbidity management
Moderator: Ms Ann Varghese (IMA World Health, US).
Togo national programme for lymphoedema management
Dr Dorkenoo summarized the three elements of the na-
tional lymphoedema management programme: detection
and referral of cases, treatment and management of cases,
and follow up and evaluation. In every village, village
chiefs and community leaders are asked to inform the
communities that anyone with a large swollen leg should
go to a clinic and this is enforced through TV and radio
announcements, posters and public criers. A national
training-of-trainers model trains nurses from throughout
the country and community health workers in seven en-
demic districts. The national programme does periodic
supervision of nurses and patient visits.
She described how the programme started in June
2007 in the seven endemic districts and was scaled up
within two years to the entire country. Even though LF
MDA ended in 2009, the number of patients continues
to increase, with over 1,200 patients currently under
treatment, and 32% of patients living in non-endemic
districts where LF MDA was not needed. Operational re-
search funds to determine the feasibility of a countrywide
morbidity control programme included start-up funding
for training, IEC material, washing kits and supervision.
The well-functioning and decentralized health system is a
good platform for the programme, with the aim to con-
tinue providing services even after the LF elimination tar-
get of 2015. The Ministry of Health continues to maintain
the LF programme coordination staff posts, even though
MDA has stopped, and provides support for supervision
activities. However, Dr Dorkenoo noted challenges with a
high turnover of trained staff and long-term compliance
of patients, necessitating refresher training and continuing
behavior change communication activities.
Community-based support for lymphoedema patients
Mr Jonathan Rout (Churches Auxiliary for Social Action,
India) described their project to provide community-
based support for lymphoedema patients in the highly-
endemic state of Orissa, where 3.5 to 6.3 million people
are estimated to be infected with LF. The multi-faceted
approach includes health education to entire communi-
ties, patient registration, extensive training, patient fol-
low up, and impact assessment. In a census of 215,515
households, 27,671 people with hand swelling, breast
swelling, hydrocele or lymphoedema were found. At
least one LF task force volunteer per village was trained
and certified in lymphoedema management and basic
first aid and, in turn, distributed posters and leaflets
door-to-door. They continue to follow closely 20 pa-
tients each. The project also supports wall paintings andstreet plays to raise awareness of MDA and footcare man-
agement, and implements classroom and field training in
lymphoedema management for school children, family
members, village volunteers, and paramedics. Patients are
provided with soap, anti-fungal cream, towels, shoes, and
a 365-day booklet to track exercises and routine hygiene.
An impact study found that quality of life improved sig-
nificantly among patients, with daily washing associated
with lower disability scores. The frequency of acute at-
tacks was the strongest predictor of disability. In addition,
a CDC study found that MDA coverage in districts with
the lymphoedema management programme (90.2%) was
better than in districts with MDA only (52-59%) or a
community-based pre-MDA education programme only
(75%) [6].
New therapeutic options for lymphoedema
Dr Achim Hoerauf (University of Bonn, Germany) pre-
sented the results of recent research that aimed to deter-
mine whether doxycycline improves filarial lymphoedema
in filarial antigen-positive patients (e.g., those with on-
going infection) as well as antigen-negative patients [7]. In
addition, it compared the effect of doxycycline, an anti-
biotic which targets Wolbachia as well as exogenous bac-
teria, to amoxicillin, an antibiotic which targets exogenous
bacteria only. The study had three treatment arms: i)
doxycycline 200 mg/day for 6 weeks and hygiene manage-
ment, ii) amoxicillin 1000 mg/day for 6 weeks and hygiene
management, and iii) placebo drug and hygiene manage-
ment. Approximately 40 patients were in each arm, the
majority of whom were in stages 1–3. Dr Hoerauf pre-
sented results that doxycycline was beneficial in revert-
ing or halting progression of early stage lymphoedema,
regardless of whether patients had active infection. The
results suggest that doxycycline might have an anti-
inflammatory effect that makes it superior to other anti-
biotics. Of those patients treated with doxycycline, 37%
showed improvement in stage, compared to 3.2% of
those treated with amoxicillin and 5.6% of those treated
with placebo. A lack of progress to more severe stages
was shown in 95% of those treated with doxycycline,
71% with amoxicillin, and 44% with placebo. There is a
need to extend this research to patients with stages 4
and higher, as well as to replicate it in other settings.
The study recommended that a 6-week course of doxy-
cycline be given to lymphoedema patients once every
two years as part of morbidity management.
African LF morbidity project
Dr Sunny Mante (African LF Morbidity Project, Ghana)
explained its goal to build capacity for filarial hydrocele
surgery, reconstructive plastic surgery for genital lym-
phoedema, and hygiene therapy for lymphoedema. A
2006 evaluation of the BMGF-supported pilot project to
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tients who had received hydrocelectomies and found
that 92% were very satisfied with the surgery. Many pa-
tients were lost to follow up because they had gone back
to work or were away for seasonal agriculture.
The project was scaled up in 10 West African coun-
tries plus Tanzania, and Malawi through funding from
Health and Development International and International
Volunteers in Urology, training 469 people in 12 coun-
tries in hydrocele surgery and operating on 3,975 pa-
tients during training. A 2007 revised surgical manual
details the technique used, which includes total removal
of the sac and no drains [8]. Since 2011, training on her-
nia surgery has been explicitly included in these train-
ings, as it is difficult to differentiate between hydrocele
and hernia patients pre-operatively and many hernia pa-
tients present for surgery when free hydrocele surgery is
offered.
Dr Mante noted that currently four workshops are
planned (two each in Ghana and Sierra Leone) through
support from International Volunteers in Urology and
Johnson & Johnson, although the project would like to
extend to East Africa and Asia. Because 25-40% of adult
males have hydrocele in highly LF-endemic areas, there
is a need to scale up provision of surgeries, provide sup-
port to hernia patients, report and evaluate surgeries
ongoing in all countries, and ensure hydrocele surgery
techniques are included in routine medicine training in
endemic countries. Capacity building of plastic surgeons
on reconstructive surgery for genital lymphoedema is
also needed. Finally, while two articles on hydrocele sur-
gery were recently published [9,10], there is a need for
more advocacy and publishing of results.
Discussion
Integration of these activities with other diseases was the
major topic of discussion. The African LF Morbidity Pro-
ject is in discussion to have joint workshops for hydrocele,
genital lymphoedema, and urogenital fistula, although it
was noted that it might be difficult to combine trainings of
district surgeons responsible for hydrocele with gynecolo-
gists who are responsible for urogenital fistula. Treating
podoconiasis patients in conjunction with lymphoedema
patients was seen as useful, given that management is
similar. In addition, the importance of having countries re-
port on these activities to WHO and collecting data from
the hospital system on number of operations, complica-
tion rate, and recurrence was raised.
Linking the programmes
New partnerships with onchocerciasis
Dr Hopkins presented a rationale for partnering with
onchocerciasis: the diseases affect overlapping popula-
tions, have almost identical disease agents, recommendsimilar treatment, employ similar M&E methods, and
face common challenges. While countries where LF and
onchocerciasis are endemic completely overlap, co-
endemicity only occurs in some districts (Figure 6).
The LF and the onchocerciasis parasites can be difficult
to distinguish, a difference which does not matter for
treatment, but does when monitoring progress toward
elimination. During preventive chemotherapy, both dis-
eases use ivermectin, while the LF programme adds alben-
dazole. For M&E, both disease programmes need better
diagnostics, as skin snips for onchocerciasis and night
blood films for LF are not popular and existing serological
tests require additional validation. There is a related need
to build human and laboratory capacity to carry out ento-
mological and parasitological surveys in both programmes.
In addition, existing M&E methods are costly and would
need to include parasitological, entomological and sero-
logical surveys for onchocerciasis elimination.
In terms of challenges common to both programmes,
there are mapping gaps for both LF and onchocerciasis, as
well as cross border issues in conflict areas, such as South
Sudan and neighbouring countries. Both programmes are
lagging behind goals for scaling up. Particularly if oncho-
cerciasis moves towards an elimination strategy, there are
18 million people (not including the Central African Re-
public, Sudan, and the Democratic Republic of Congo)
who live in areas with a nodule prevalence between 5-15%
that are not currently being treated. Eighty percent of the
people not yet covered by LF treatment live in nine coun-
tries, many of which are either treating for onchocerciasis,
such as Nigeria, or have found new areas of onchocerciasis
endemicity that also need treatment, such as in Ethiopia.
Finally, loiasis presents a major obstacle for both pro-
grammes in co-endemic areas in central Africa, such as
Cameroon, the Democratic Republic of Congo, Congo,
Gabon, and Equatorial Guinea, with 30 million people
at-risk for loiasis (based on those living in areas with
greater than 20% on the RAPLOA scale). In areas where
onchocerciasis is meso- or hyper-endemic and co-
endemic with loaisis, treatment can still occur. However,
given that only 1-2% of people might be infected in
areas where LF treatment is prescribed, it is too risky to
treat with ivermectin in areas with loiasis, given the
chance of serious adverse events due to high levels of
Loa microfilaremia. The LF programme is now moving
forward with a strategy of using twice annual albenda-
zole and bednets in these areas.
Dr Hopkins concluded that there are many opportun-
ities for synergy including integrated mapping, joint train-
ing, combined treatment registers, simultaneous MDA,
joint M&E, and joint epidemiological evaluations. He
challenged the group to not just see the benefit in exploit-
ing synergies for the two programmes, but to see the LF
and onchocerciasis activities as one programme in Africa.
Figure 6 Overlap between LF and onchocerciasis in Africa. Legend: A: Lymphatic Filariasis current status (Source: AFRO NTD programme).
B: Onchocerciasis treatment areas (Source: APOC).
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Dr David Addiss (Children Without Worms, USA) pre-
sented a summary of ancillary benefits from the LF MDA
programme. The LF programme has given the STH com-
munity a bold vision of elimination, with a platform for in-
tegrated NTD activities related to MDA and M&E. From
2001 to 2011, LF MDA included two billion treatments
with albendazole that also treated STH. For example, in
2010, WHO reported that 57% of the school-aged children
treated for STH were given these medicines through na-
tional LF programmes. In areas with LF programmes, en-
tire communities are treated for LF, which likely gives a
greater impact than those areas that only implement
school-based STH treatment. In terms of M&E, the LF
TAS platform could be used to collect information on
STH as well.
However, Dr Addiss cautioned that often the benefits
of LF programme have not been fully extended to those
with LF-related disease. The rationale for the two pillars
of the LF programme stems from the wording of the
World Health Assembly resolution – elimination as a
public-health problem – which includes those with clin-
ical disease, and not just infection. Providing care for
LF-related disease has also been shown to increase ac-
ceptability and compliance with MDA. Furthermore,
providing care for those with LF-related disease wasconsidered the right and compassionate thing to do. But
as of 2010, only 27 (33%) of endemic countries had ac-
tive morbidity management programmes.
The four basic components of NTD control include
preventive chemotherapy (which is usually the largest
component and often has a direct clinical benefit); vector
control; water, sanitation and hygiene; and clinical care. In
the LF programme, morbidity management and disability
prevention (MMDP) lags behind PC, while in the STH
programme, the water, sanitation and hygiene activities
likewise take a back seat to PC. The trachoma programme,
however, has a more balanced approach with the four
components of the SAFE strategy – surgery, antibiotics,
facial cleanliness, and environmental improvement. For
the LF programme to truly achieve elimination, it needs to
be both internally integrated in terms of MDA, vector
control and MMDP activities, as well as externally inte-
grated with other health programmes. A model for how
MMDP can be integrated externally has been described in
the Legs to Stand On framework, which identifies the
common elements of treatment across diseases such as
LF, diabetes, leprosy, and Buruli ulcer.
Dr Addiss related another benefit of the GPELF in
context of a quote from Bill Foege about ‘seeing the
faces’ behind everything we do - i.e., having a compas-
sionate response to suffering. The GPELF represents a
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included the three main elements of compassion, which
include: i) awareness of suffering, ii) empathy, and iii)
action. Publications focusing on the awareness of suffer-
ing include studies of psychological distress and disabil-
ity caused by LF-related diseases. In terms of emotional
attunement with patients, he related the power of the
personal story - of 'seeing the faces' for those who work
in LF elimination. Finally, compassion must lead to action.
The magnitude of action in the global LF programme is,
by any standard, impressive. Although the GPELF is a
great example of a ‘mass uprising of compassion’, the
expression of that compassion faces several important
challenges. It is difficult to keep seeing the faces when
working with populations in the millions and billions, and
across great geographical distances. In addition, a global
programme requires acting through complex systems of
institutions, each with its own agenda, and with compet-
ing motivations. Dr Addiss challenged the group to try to
maintain focus on interrupting LF transmission while
expanding its peripheral vision to include those with LF
disease; to unite the LF programme activities across differ-
ent sectors in the health system; to see faces and numbers
at the same time; and to combine compassion for individ-
uals with action at the population level.
Two programmes: a shared goal – LF and trachoma
Dr Teshome Gebre (International Trachoma Initiative
(ITI), Ethiopia) discussed the shared goals and common-
alities between LF and trachoma. Both diseases are ac-
quired in childhood, with terribly painful and severely
incapacitating complications that appear later in life. In
Africa, there are mapping gaps in nine countries for LF
and 19 for trachoma; coordinated mapping could occur
in areas of potential overlap to leverage resources. Both
programme strategies include MDA and morbidity man-
agement, while trachoma also includes the preventive
activities of face washing and environmental improve-
ment. In order to achieve trachoma goals by 2020, there
is a backlog of 4.6 million trichiasis patients that need
surgery, which means scaling up from 160,000 surgeries
to 500,000 surgeries a year. While more than 200 million
trachoma treatments have been delivered since 1998,
380 million more are needed before 2020. Dr Gebre dis-
cussed various ideas for linking the programme inter-
ventions including: i) empowering CDDs to handle all
MDA through joint planning, training, and implementa-
tion; ii) co-administration of drugs where feasible, depend-
ing on results of clinical trials underway for ivermectin,
albendazole and azithromycin; iii) joint M&E, and iv) initi-
ation of regional, sub-regional, and national NTD coord-
ination mechanisms or annual reviews which are smaller
and more technical, using the sub-regional forums to
address cross-border issues. Beyond just LF and otherNTDs, he proposed links with HIV/AIDS, tuberculosis,
and malaria, such as a ‘MalTra’ week approach to reach
several million people with MDA and bednets in Ethiopia.
He then discussed the unresolved issues that are ham-
pering achievement of goals, such as gaps in behavior
change, hygiene and sanitation, and effective community
mobilization strategies. There are concerns with results
of MDA coverage surveys; for example, Ethiopia found
less than 49% coverage in surveys when health facilities
reported over 85% coverage. This has translated into im-
pact assessments that have shown that very few districts
showed infection levels of TF less than 10% after three
or five rounds and so must continue MDA. Finally, the
NTD community needs to find the most effective level
of integration and coordination among partners and do-
nors at all levels. He cautioned that if the LF and trach-
oma programmes do not start doing things differently
the 2020 elimination goal will not be achieved.
A partnership with malaria programmes
Dr Richards discussed the Nigerian experience in linking
LF with the malaria programme, where Anopheles gam-
biae is the primary vector of both diseases. A 2011
WHO position statement on integrated vector manage-
ment (IVM) made the case that the policy of using IVM
to control malaria and LF makes epidemiologic sense
[10]. In Plateau and Nasarawa States in Central Nigeria,
the Carter Center has been implementing LF activities
integrated with onchocerciasis, schistosomiasis and mal-
aria since 1998. During that period the programme has
dissected over 80,000 mosquitoes as part of LF entomo-
logical monitoring, using the percentages of any larval
stage (L1, L2, and L3 but not including mf stages) and
only infective stage larvae (L3) as the critical indicators.
The programme saw mosquito rates of infection with
any stage larvae decrease during MDA, for an average
reduction of 85% from 3.1% to 0.3% in 2010, after at
least 7 years of MDA (Figure 7). L3 also were sporadic-
ally found in dissections.
In 2010, several million long-lasting insecticidal nets
(LLINs) – two nets for every household - were distrib-
uted in Plateau and Nasarawa States as part of a massive
campaign throughout Nigeria to distribute over 65 mil-
lion LLIN. A year after LLIN distribution, entomological
monitoring in LF sentinel villages recorded 0% mosqui-
toes infected with L3 larvae, as well as 0% mosquitoes
infected with any larval stage. Preliminary results from
2012 are also showing no infected mosquitoes. Thus,
there is synergy between LLIN and MDA.
In southeastern Nigeria, where MDA cannot be pro-
vided due to concerns about adverse reactions from co-
endemic loiasis infection, the Carter Center has studied
the entomological impact of LLIN alone (without MDA)
in reducing LF transmission. The use of LLIN alone
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Figure 7 Average mosquito LF infection rates in nine sentinel
villages. Legend: Based on >46,000 dissections. blue rectangle =
Infected.
Brady Parasites & Vectors 2014, 7:46 Page 16 of 19
http://www.parasitesandvectors.com/content/7/1/46showed an 84% reduction in all larval mosquito infection
rates, compared to areas with LLINs and MDA, where
100% reduction was shown. In 2011 in both these areas,
no L3 stage larvae were found. This indicates that trans-
mission of LF has stopped – although in LLIN areas it
might not be interrupted since halting LLIN use could
result in a rapid return of transmission.
Over 90% of Nigeria has been mapped for LF, with
over 106 million people found to be at risk in 541 local
government areas (LGAs). However, only 19% of LGAs
are currently implementing MDA for LF. In contrast, al-
most all states completed the distribution of LLINs in
2012, and will complete the job in early 2013. If the re-
sults from the entomological impact studies hold true
elsewhere in areas with good LLIN coverage in Africa, LF
programmes can celebrate a major impact on LF trans-
mission now, despite the fact that MDA scale-up is lag-
ging. GAELF partners should encourage, and indeed help,
the malaria programme reach its LLIN coverage and usage
goals, as it is to the LF programme’s advantage!
Building on advocacy efforts using political figures
such as former head of state General Dr Yakuku Gowon,
the Carter Center sponsored a national combined LF
and malaria programme meeting in March 2012. The
meeting presented the entomological monitoring find-
ings, planned scale up of both LF and malaria activities,
and created awareness about the benefits of integration,
such as the fact that infection with intestinal worms can
worsen malaria outcomes. Another benefit is that LF
MDA, which intensively targets hookworm through distri-
bution of albendazole to entire communities, results in
lower anemia prevalence. Severe anemia accounts for half
of all malarial deaths in African children and women,
co-infection with malaria and intestinal worms has been
shown to result in greater anemia. In addition, LF
community-based networks can be used by the malaria
programme to mop up LLIN distribution, and implementannual monitoring of LLIN ownership, usage and condi-
tion. Finally, behaviour change communication can be
strengthened by showing the protection offered by LLINs
from both malaria and LF, as focus groups showed that
adults are more motivated to sleep under nets to protect
themselves from lymphoedema and hydrocele than from
malaria fever, which is seen as an infection of young
children.
Discussion
Dr Adiele Onyeze (WHO Africa Regional Office) asked
how the global LF community could scale up these ap-
proaches at national or regional levels. He related the
WHO African Region strategy of the ‘4 1’s approach’ that
includes common partnership, planning, delivery and
M&E, with a goal of making life better for fellow human
beings at risk or already infected. The African Region’s
priority is to have NTD national plans and fora by 2013,
with new regional programme review group mechanisms
at a regional level. The most difficult component of the
NTD work in Africa goes beyond the availability of drugs
and tools to figuring out how to bring various targets, or-
ganizations and personalities together.
Participants agreed that there is a moral imperative to
look at synergies in collaboration and coordination. It is
important to clearly state the LF community’s needs
from other programmes, e.g. what exactly do we want
from the malaria, water, morbidity and health system
strengthening programmes and organizations? We need
to articulate how the LF programme can help other pro-
grammes achieve their goals. The LF programme needs
strong advocates and quality data to persuade other pro-
grammes that “we are not just there for the money”. The
challenges of translating the good examples of collabor-
ation in these presentations into other country settings
was discussed, including the difficulties of replication in
different settings, and the need for new programmes to
have access to this information.
GAELF: the next chapter
Moderator: Dr Mwele Malecela.
Dr Malecela (National Institute for Medical Research,
Tanzania) opened the final session by sharing a Swahili
saying: ‘in order to see how far you have come, look
back and see where you were’. She reflected that GPELF
has made great progress since 2000 – with stronger na-
tional programmes, great country leadership, a focus on
countries and the patients, and an acknowledgement of
the importance of good data and research.
Strategic partnerships
Dr Neeraj Mistry (Global Network for NTDs, USA) dis-
cussed the key elements to strategic partnerships at a coun-
try level, including trust, clear objectives, and specific roles
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should focus on partner competencies, such as involving
business people who have better training in logistics and
distribution than medical doctors. Programmes need to
understand the motivation that each partner has to be in-
volved, whether it is the use of their logo, a free t-shirt, or
raising their public profile. For programmes (and partner-
ships) to work, charismatic leadership is necessary to con-
vince governments and partners to support NTD work.
The GAELF should cultivate national programme leaders
who have the ability and trust to negotiate partnerships at
country level.
He then offered some examples of potential partner-
ships, such as car dealerships lending vehicles during
MDA, mobile phone companies donating costs of text-
ing MDA reports, cinema groups showing awareness
raising short movies in mobile cinemas in rural areas,
local artists or celebrities advocating for NTDs, or com-
panies donating t-shirts. Dr Mistry recommended that
national programme reviews include outsiders from busi-
ness or media in order to get a different perspective on
programme success and challenges. He mentioned that a
full assessment of the links between HIV/AIDS, tubercu-
losis, and malaria and NTDs has been sent to the Global
Fund for AIDS, Tuberculosis and Malaria (GFATM) to en-
courage them to approve proposals which include NTD
activities. Finally, he implored the group to use its anger at
injustice to advocate on behalf of NTDs as we are the only
voice of many of these communities.
Future of GAELF in post-London declaration environment
Professor David Molyneux (Liverpool School of Tropical
Medicine Centre for Neglected Tropical Diseases, UK)
discussed the role of GAELF in the greater context of a
changing global health, economic and political environ-
ment. He highlighted steps in the evolution of the fight
against LF, including: pharmaceutical company support;
BMGF seed funding; delineation of the role of the
GAELF in coordination, resource mobilization and advo-
cacy; emergence of the concept of NTDs; and USAID
support.
Since 2000, with support from endemic countries,
BMGF, DFID, USAID and others, there have been 2 billion
cumulative treatments for LF, one of the most rapidly
upscaling public health programmes. GAELF has been
used as an umbrella to capture a diversity of partners, learn
from country experience, and focus on a particular goal,
while recognizing the complexity of problem. GAELF’s
strengths are in its loose structure, ability to speak inde-
pendently, and as a forum for communication between
country programmes, researchers and donors. However,
more funds are needed to expand morbidity activities,
meet elimination goals, and implement critical operational
research. The Representative Contact Group is not yet fullyrepresentative of the broader constituency. Innovative
funding mechanisms, whether centralized funding at
the World Bank, from APOC, the GFATM or other
models, need to be explored.
Professor Molyneux expressed his vision of keeping
GAELF focused on LF and the elimination goal, but adapt-
ing to upscale PC for all NTDs given that if LF reaches its
target for MDA, a high proportion of PC objectives will be
met as well. Instead of one NTD alliance, GAELF would
be one in a mix of alliances that would link to the others
at different levels, through articulating specific operational
research priorities, global advocacy, and capacity building
for data management, logistics and clinical issues.
Discussion
The possibility of having a resident technical advisor in
place for key countries (following the example of the
guinea worm eradication programme), who sits with the
national programme but has the freedom to talk with
other ministries, private sector and stakeholders was dis-
cussed. Other methods of providing support included i)
continuing forums like GAELF to ensure opportunities
for discussion among many stakeholders, ii) twinning suc-
cessful countries with those needing assistance or just
starting, and iii) broadening GAELF’s reach to include
more African and Indian research centres and universities.
While participants agreed with keeping the GAELF as an
LF-specific alliance, the idea was put forward of a three-
in-one concept of combining parts of LF, STH and oncho-
cerciasis meetings or holding them back-to-back.
Next steps
Dr Lammie introduced the newly elected Executive
Group members: Patrick Lammie, Moses Bockarie,
Frank Richards, Adrian Hopkins, Charles Mackenzie,
and Njeri Wamae. He then thanked all the speakers for
preparing thought-provoking, quality presentations and
listed five key recommendations that had emerged from
the meeting:
1. Inspirational stories from countries showed clear
examples of the quality of country leadership in the
GAELF, with leaders who are problem solvers and
have the ability to motivate governments and
partners to contribute. Since good programme
managers make good programmes, support needs to
continue to these programme managers. The idea of
a mentorship programme, perhaps through the
WHO capacity building working group, in which
new programme managers could shadow more
experienced managers through an MDA cycle,
should be explored. In addition, the idea of resident
advisors should be taken forward, especially in
countries with a single NTD programme manager.
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potential threat to the GPELF to an opportunity to
scale up LF, as well as other NTD activities.
Countries provided examples from building LF
MDA onto onchocerciasis CDD in Sierra Leone and
Liberia to child health days in the Philippines to
lowering LF prevalence through use of bednets in
Nigeria to the use of LF MDA as the single largest
mechanism for STH delivery. However, evaluation of
the impact of integration is missing, with priorities
to strengthen evaluation capacity and operational
research in mapping, elimination criteria and
post-MDA surveillance needed.
3. The willingness to see the faces in the data is a clear
challenge. Thus far, in many countries, the
programmes have been highlighting people with
disability to leverage community compliance with
MDA without providing care for them. This needs
to change by the time of the next GAELF meeting.
4. The single greatest determinant of success at
country level has been government commitment.
The idea of GAELF representatives visiting key
countries with WHO and other donors to galvanize
support at country level should be taken forward.
5. There is a challenge to be innovative in the way
GAELF is organized, both in terms of the
mechanism of engaging the Representative Contact
Group and in how it coordinates with other
disease-specific and NTD meetings. Anyone with
suggestions on how best to ensure greater country
participation and engagement, as well as more
effective use of meeting time, was encouraged to
send an email through the GAELF website.
Dr Lammie expressed gratitude to Don Bundy and the
World Bank, Julie Jacobson, and the Global Health Strat-
egies team and the CNTD team for organizing the meet-
ings and to the outgoing Executive Group members for
putting together the series of panel discussions. Finally,
he gave thanks to the 65 countries represented, and the
enormous commitment by donors including Merck &
Co. Inc. and GSK, as well as the many partners that have
supported NTD programmes at country level and sup-
ported partners to attend the meeting.
Don Bundy closed the meeting by sharing his impres-
sions of the NTD and GAELF meetings. In the 1980s,
LF control was based on vector control, with the only
medical input at the clinical and immunological levels.
The community is now too focused on preventive
chemotherapy, a change facilitated by the drug dona-
tions targeting LF. Since incentives are the key to
change, he challenged GAELF to continue exploring the
reasons for working together and what information
needs to be shared.Endnote
aWhen South Sudan became independent in 2011, the
number of endemic countries rose from 72 to 73.Additional file
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